Demetrix, Inc.

Demetrix, Inc. is a biotechnology company specializing in developing innovative solutions for the production of cannabinoids and other complex natural products through fermentation technology. Founded in 2015 and headquartered in Emeryville, US, Demetrix, Inc. focuses on biotechnology applications in cannabinoid production.

The company has executed 6 deals, with its most recent funding round completed on February 10, 2021, raising USD 19. 09 mn in venture capital. Jeff Ubersax, the CEO, has significant expertise in the biotechnology field, further driving the company’s innovative strategies. Demetrix, Inc.

offers a diverse range of products and services that cater to various customer segments. Its core offerings include advanced fermentation solutions that enable the production of cannabinoids, providing tailored approaches that address operational challenges faced by businesses in the healthcare, e-commerce, and hospitality industries. The company targets a global clientele, with substantial market penetration in North America, Europe, and parts of Asia, serving both large enterprises and small to medium-sized businesses. Demetrix, Inc.

's revenue model is structured around subscription-based services and B2B partnerships, facilitating steady income streams through long-term contracts. Clients typically engage in transactions involving tiered pricing plans based on usage levels or specific feature sets. This structured approach allows for predictable revenue generation while addressing diverse market demands. Looking ahead, Demetrix, Inc.

aims to expand its product offerings by launching new fermentation technologies aimed at increasing efficiency and reducing costs. The company plans to enter new markets, specifically targeting regions in Europe and Asia, by the end of 2023. The recent funding of USD 19. 09 mn will be strategically utilized to support these initiatives, ensuring the development and launch of upcoming products and facilitating market expansion.